Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4173258
Max Phase: Preclinical
Molecular Formula: C22H31N3O
Molecular Weight: 353.51
Molecule Type: Small molecule
Associated Items:
ID: ALA4173258
Max Phase: Preclinical
Molecular Formula: C22H31N3O
Molecular Weight: 353.51
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: C#CCN(C)Cc1cc2cc(OCCCN3CCCCC3)ccc2n1C
Standard InChI: InChI=1S/C22H31N3O/c1-4-11-23(2)18-20-16-19-17-21(9-10-22(19)24(20)3)26-15-8-14-25-12-6-5-7-13-25/h1,9-10,16-17H,5-8,11-15,18H2,2-3H3
Standard InChI Key: NQDGCGNKNJWZHP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 353.51 | Molecular Weight (Monoisotopic): 353.2467 | AlogP: 3.50 | #Rotatable Bonds: 8 |
Polar Surface Area: 20.64 | Molecular Species: BASE | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 9.22 | CX LogP: 3.16 | CX LogD: 0.96 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.54 | Np Likeness Score: -1.33 |
1. Bautista-Aguilera ÓM, Budni J, Mina F, Medeiros EB, Deuther-Conrad W, Entrena JM, Moraleda I, Iriepa I, López-Muñoz F, Marco-Contelles J.. (2018) Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile., 61 (15): [PMID:29969030] [10.1021/acs.jmedchem.8b00848] |
2. Łażewska D, Olejarz-Maciej A, Kaleta M, Bajda M, Siwek A, Karcz T, Doroz-Płonka A, Cichoń U, Kuder K, Kieć-Kononowicz K.. (2018) 4-tert-Pentylphenoxyalkyl derivatives - Histamine H3 receptor ligands and monoamine oxidase B inhibitors., 28 (23-24): [PMID:30404719] [10.1016/j.bmcl.2018.10.048] |
3. Rodríguez-Soacha DA, Scheiner M, Decker M.. (2019) Multi-target-directed-ligands acting as enzyme inhibitors and receptor ligands., 180 [PMID:31401465] [10.1016/j.ejmech.2019.07.040] |
4. Mishra P, Kumar A, Panda G.. (2019) Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018)., 27 (6): [PMID:30744931] [10.1016/j.bmc.2019.01.025] |
Source(1):